Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin α, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 3, 2004, Pages 739-746

  Petersen, Peter J ^a   Wang, T Z ^a   Dushin, Russell G ^a   Bradford, Patricia A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC98 6446; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; ERYTHROMYCIN; GLYCOPEPTIDE; LEVOFLOXACIN; MANNOPEPTIMYCIN ALPHA; NATURAL PRODUCT; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN;

EID: 1442275730     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.3.739-746.2004     Document Type: Article

References (37)

1. Andrews, J., J. Ashby, G. Jevons, N. Lines, and R. Wise. 1999. Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997. J. Antimicrob. Chemother. 43:689-698.
2. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin, United States, 2002. Morbid. Mortal. Wkly. Rep. 51:565-567.
3. Chien, J. W., M. L. Kucia, and R. A. Salata. 2000. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30:146-151.
4. Chu, D. T. 1999. Recent developments in macrolides and ketolides. Curr. Opin. Microbiol. 2:467-474.
5. Chu, D. T. 1999. Recent progress in novel macrolides, quinolones, and 2-pyridones to overcome bacterial resistance. Med. Res. Rev. 19:497-520.
6. Dankert, J., Y. Holloway, W. Joldersma, and J. Hess. 1983. Importance of minimizing carry-over effect at subculture in the detection of penicillin-tolerant viridans group streptococci. Antimicrob. Agents Chemother. 23:614-616.
7. Diekema, D. I., and R. N. Jones. 2000. Oxazolidinones: a review. Drugs 59:7-16.
8. Facklam, R., and D. Collins. 1989. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 37:534-541.
9. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.
10. Garcia-Garrote, F., E. Cercenado, L. Alcala, and E. Bouza. 1998. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. Antimicrob. Agents Chemother. 42:2452-2455.
11. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.
12. Green, S. L., L. C. Maddox, and E. D. Huttenbach. 2001. Linezolid and reversible myelosuppression. JAMA 285:1291.
13. Harland, S., S. E. Tebbs, and T. S. Elliott. 1998. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother. 41:273-276.
14. He, H., R. T. Williamson, B. Shen, E. I. Graziani, H. Y. Yang, S. M. Sakya, P. J. Petersen, and G. T. Carter. 2002. Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124:9729-9736.
15. Jones, R. N., D. E. Low, and M. A. Pfaller. 1999. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. 33:101-112.
16. Jones, R. N., S. A. Marshall, M. A. Pfaller, W. W. Wilke, R. J. Hollis, M. E. Erwin, M. B. Edmond, R. P. Wenzel, et al. 1997. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn. Microbiol. Infect. Dis. 29:95-102.
17. Kim, K. S., and B. F. Anthony. 1981. Importance of bacterial growth phase in determining minimal bactericidal concentrations of penicillin and methicillin. Antimicrob. Agents Chemother. 19:1075-1077.
18. Lamb, H. M., D. P. Figgitt, and D. Faulds. 1999. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 58:1061-1097.
19. Lucet, J. C. 1998. Control of multiple-resistant bacteria. Rev. Praticien. 48:1541-1546.
20. Malathum, K., T. M. Coque, K. V. Singh, and B. E. Murray. 1999. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria. Antimicrob. Agents Chemother. 43:930-936.
21. Marshall, S. A., W. W. Wilke, M. A. Pfaller, and R. N. Jones. 1998. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn. Microbiol, Infect. Dis. 30:205-214.
22. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines, M26-A, vol. 19. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A5, vol. 20. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Pavan, B. 2000. Synercid. Curr. Opin. Investig. Drugs 1:173-180.
25. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
26. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
27. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, K. C. Kugler, M. L. Beach, et al. 1999. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 33:283-297.
28. Pfaller, M. A., R. N. Jones, S. A. Marshall, M. B. Edmond, R. P. Wenzel, et al. 1997. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. Diagn. Microbiol. Infect. Dis. 29:259-263.
29. Ruzin, A., G. Singh, A. Severin, Y. Yang, R. G. Dushin, A. G. Sutherland, A. Minnick, M. Greenstein, M. K. May, D. M. Shlaes, and P. A. Bradford. 2004. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob. Agents Chemother. 48:729-739.
30. Singh, M. P., P. J. Petersen, W. J. Weiss, J. E. Janso, S. W. Luckman, E. B. Lenoy, P. A. Bradford, R. T. Testa, and M. Greenstein. 2003. Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob. Agents Chemother. 47:62-69.
31. Stratton, C. W., and R. C. Cooksey. 1991. Susceptibility tests: special tests, p. 1153-1165. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
32. Sum, P. E., and P. Petersen. 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9:1459-1462.
33. Tally, F. P., M. Zeckel, M. M. Wasilewski, C. Carini, C. L. Berman, G. L. Drusano, and F. B. Oleson, Jr. 1999. Daptomycin: a novel agent for gram-positive infections. Exp. Opin. Investig. Drugs 8:1223-1238.
34. Tenover, F. C. 1999. Implications of vancomycin-resistant Staphylococcus aureus. J. Hosp. Infect. 43:S3-S7.
35. Testa, R. T., P. J. Petersen, N. V. Jacobus, P. E. Sum, V. J. Lee, and F. P. Tally. 1993. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother. 37:2270-2277.
36. Weinstein, M. P., M. L. Towns, S. M. Quartey, S. Mirrett, L. G. Reimer, G. Parmigiani, and L. B. Reller. 1997. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin. Infect. Dis. 24:584-602.
37. Zeckel, M. L., D. A. Preston, and B. S. Allen. 2000. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob. Agents Chemother. 44:1370-1374.